896 related articles for article (PubMed ID: 32821086)
21. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
[TBL] [Abstract][Full Text] [Related]
22. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
23. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
[TBL] [Abstract][Full Text] [Related]
24. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
25. [Remdesivir, the antiviral hope against SARS-CoV-2].
Reina J
Rev Esp Quimioter; 2020 Jun; 33(3):176-179. PubMed ID: 32239125
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
27. Current pharmacological treatments for SARS-COV-2: A narrative review.
Nittari G; Pallotta G; Amenta F; Tayebati SK
Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692
[TBL] [Abstract][Full Text] [Related]
28. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
29. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
30. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Wang M; Cao R; Zhang L; Yang X; Liu J; Xu M; Shi Z; Hu Z; Zhong W; Xiao G
Cell Res; 2020 Mar; 30(3):269-271. PubMed ID: 32020029
[No Abstract] [Full Text] [Related]
31. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
32. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
[TBL] [Abstract][Full Text] [Related]
33. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
Dobrovolny HM
Virology; 2020 Nov; 550():61-69. PubMed ID: 32882638
[TBL] [Abstract][Full Text] [Related]
34. Remdesivir: First Approval.
Lamb YN
Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
[TBL] [Abstract][Full Text] [Related]
35. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
36. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
Taha HR; Keewan N; Slati F; Al-Sawalha NA
Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
[TBL] [Abstract][Full Text] [Related]
37. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):585-586. PubMed ID: 32439198
[TBL] [Abstract][Full Text] [Related]
38. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
Aleissa MM; Silverman EA; Paredes Acosta LM; Nutt CT; Richterman A; Marty FM
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139290
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
Kokic G; Hillen HS; Tegunov D; Dienemann C; Seitz F; Schmitzova J; Farnung L; Siewert A; Höbartner C; Cramer P
Nat Commun; 2021 Jan; 12(1):279. PubMed ID: 33436624
[TBL] [Abstract][Full Text] [Related]
40. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]